Extracellular Matrix and Growth Factor Engineering for Controlled Angiogenesis in Regenerative Medicine

Blood vessel growth plays a key role in regenerative medicine, both to restore blood supply to ischemic tissues and to ensure rapid vascularization of clinical-size tissue-engineered grafts. For example, vascular endothelial growth factor (VEGF) is the master regulator of physiological blood vessel growth and is one of the main molecular targets of therapeutic angiogenesis approaches. However, angiogenesis is a complex process and there is a need to develop rational therapeutic strategies based on a firm understanding of basic vascular biology principles, as evidenced by the disappointing results of initial clinical trials of angiogenic factor delivery. In particular, the spatial localization of angiogenic signals in the extracellular matrix (ECM) is crucial to ensure the proper assembly and maturation of new vascular structures. Here, we discuss the therapeutic implications of matrix interactions of angiogenic factors, with a special emphasis on VEGF, as well as provide an overview of current approaches, based on protein and biomaterial engineering that mimic the regulatory functions of ECM to optimize the signaling microenvironment of vascular growth factors.

[1]  C. Heldin,et al.  Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain. , 1991, Cell regulation.

[2]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[3]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[4]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[5]  Gul A. Agha,et al.  Strategic directions , 1996, IEEE Parallel Distributed Technol. Syst. Appl..

[6]  Takayuki Asahara,et al.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb , 1996, The Lancet.

[7]  H. Blau,et al.  VEGF gene delivery to muscle: potential role for vasculogenesis in adults. , 1998, Molecular cell.

[8]  H. Blau,et al.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.

[9]  A. Nagy,et al.  Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. , 2000, Development.

[10]  L. Kedes,et al.  Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. , 2000, Journal of the American College of Cardiology.

[11]  Peter Carmeliet,et al.  VEGF gene therapy: stimulating angiogenesis or angioma-genesis? , 2000, Nature Medicine.

[12]  E. Schönherr,et al.  Extracellular Matrix and Cytokines: A Functional Unit , 2000, Developmental immunology.

[13]  Dian Feng,et al.  Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.

[14]  H. Blau,et al.  The well-tempered vessel , 2001, Nature Medicine.

[15]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[16]  E. Manseau,et al.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.

[17]  R. Linhardt,et al.  Heparin-protein interactions. , 2002, Angewandte Chemie.

[18]  Holger Gerhardt,et al.  Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. , 2002, Genes & development.

[19]  S. Ylä-Herttuala,et al.  Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ , 2002, The journal of gene medicine.

[20]  K. Sugimachi,et al.  Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2 , 2002, Circulation research.

[21]  Kenneth M. Yamada,et al.  Integrin regulation of growth factor receptors , 2002, Nature Cell Biology.

[22]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[23]  L. Trusolino,et al.  Interactions between growth factor receptors and adhesion molecules: breaking the rules. , 2003, Current opinion in cell biology.

[24]  Guido Tarone,et al.  Positional control of cell fate through joint integrin/receptor protein kinase signaling. , 2003, Annual review of cell and developmental biology.

[25]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[26]  Martin Ehrbar,et al.  Cell‐demanded release of VEGF from synthetic, biointeractive cell‐ingrowth matrices for vascularized tissue growth , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  U. Landegren,et al.  Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. , 2003, Genes & development.

[28]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[29]  S. Ylä-Herttuala,et al.  Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. , 2004, Trends in cardiovascular medicine.

[30]  Jeffrey A. Hubbell,et al.  Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth , 2004, Circulation research.

[31]  H. Blau,et al.  Critical role of microenvironmental factors in angiogenesis , 2005, Current atherosclerosis reports.

[32]  S. Ylä-Herttuala,et al.  Blood Flow Remodels Growing Vasculature During Vascular Endothelial Growth Factor Gene Therapy and Determines Between Capillary Arterialization and Sprouting Angiogenesis , 2005, Circulation.

[33]  Jacqueline Murray,et al.  Heparin-II Domain of Fibronectin Is a Vascular Endothelial Growth Factor-Binding Domain: Enhancement of VEGF Biological Activity by a Singular Growth Factor/Matrix Protein Synergism , 2006, Circulation research.

[34]  M. Merchant,et al.  The FASEB Journal • FJ Express Full-Length Article Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia , 2022 .

[35]  Robert J Fisher,et al.  Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. , 2006, Biomaterials.

[36]  David J Mooney,et al.  Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. , 2007, Cardiovascular research.

[37]  L. Norgren,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.

[38]  David Silverstein,et al.  Growth factor binding to the pericellular matrix and its importance in tissue engineering. , 2007, Advanced drug delivery reviews.

[39]  Holger Gerhardt,et al.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.

[40]  Glenn D Prestwich,et al.  Release of basic fibroblast growth factor from a crosslinked glycosaminoglycan hydrogel promotes wound healing , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[41]  Matthias P Lutolf,et al.  Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. , 2007, Biomaterials.

[42]  J. Schalkwijk,et al.  Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. , 2007, Biomaterials.

[43]  D. Mooney,et al.  Polymers for pro- and anti-angiogenic therapy. , 2007, Biomaterials.

[44]  Antonios G Mikos,et al.  Strategic directions in tissue engineering. , 2007, Tissue engineering.

[45]  Holger Gerhardt,et al.  Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. , 2008, Journal of theoretical biology.

[46]  Jeroen Rouwkema,et al.  Vascularization in tissue engineering. , 2008, Trends in biotechnology.

[47]  J. Hubbell,et al.  The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. , 2008, Biomaterials.

[48]  Olena Kravchuk,et al.  Vitronectin: growth factor complexes hold potential as a wound therapy approach. , 2008, The Journal of investigative dermatology.

[49]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[50]  Jeff W Lichtman,et al.  Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors , 2009, Proceedings of the National Academy of Sciences.

[51]  G. Schultz,et al.  Interactions between extracellular matrix and growth factors in wound healing , 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[52]  Jörn Tongers,et al.  Human studies of angiogenic gene therapy. , 2009, Circulation research.

[53]  L. Zentilin,et al.  Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. , 2009, Cardiovascular research.

[54]  Andrés J. García,et al.  Update on therapeutic vascularization strategies. , 2009, Regenerative medicine.

[55]  I. Martin,et al.  Adipose tissue‐derived progenitors for engineering osteogenic and vasculogenic grafts , 2010, Journal of cellular physiology.

[56]  D. Mooney,et al.  Growth factor delivery-based tissue engineering: general approaches and a review of recent developments , 2011, Journal of The Royal Society Interface.

[57]  Michael Höpfner,et al.  The shunt problem: control of functional shunting in normal and tumour vasculature , 2010, Nature Reviews Cancer.

[58]  Mikaël M. Martino,et al.  The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  M. Heberer,et al.  High‐Throughput Flow Cytometry Purification of Transduced Progenitors Expressing Defined Levels of Vascular Endothelial Growth Factor Induces Controlled Angiogenesis In Vivo , 2009, Stem cells.

[60]  S. Ylä-Herttuala,et al.  New aspects in vascular gene therapy. , 2010, Current opinion in pharmacology.

[61]  J. Turnbull,et al.  Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. , 2011, The Journal of endocrinology.

[62]  J. Leor,et al.  The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. , 2011, Biomaterials.

[63]  Ralph Müller,et al.  Engineering the Growth Factor Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue Healing , 2011, Science Translational Medicine.

[64]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[65]  M. Giacca,et al.  Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle , 2011, Gene Therapy.

[66]  Yadong Wang,et al.  Therapeutic angiogenesis: controlled delivery of angiogenic factors. , 2012, Therapeutic delivery.

[67]  T. Carrel,et al.  Controlled angiogenesis in the heart by cell-based expression of specific vascular endothelial growth factor levels. , 2012, Human gene therapy methods.

[68]  L. Gurke,et al.  FACS-purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia , 2011, Journal of cellular and molecular medicine.

[69]  M. Merchant,et al.  Therapeutic angiogenesis due to balanced single‐vector delivery of VEGF and PDGF‐BB , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  M. Giacca,et al.  VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond , 2012, Gene Therapy.

[71]  W. Murphy,et al.  Specific VEGF sequestering and release using peptide-functionalized hydrogel microspheres. , 2012, Biomaterials.

[72]  B. Annex,et al.  Therapeutic angiogenesis for critical limb ischaemia , 2013, Nature Reviews Cardiology.

[73]  Jeffrey J. Rice,et al.  Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain , 2013, PloS one.

[74]  M. Trani,et al.  Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent. , 2013, Human gene therapy methods.

[75]  W. R. Taylor,et al.  Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes. , 2013, Biomaterials.

[76]  D. Mooney,et al.  Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. , 2013, Biomaterials.

[77]  Mikaël M. Martino,et al.  The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165. , 2013, Biomaterials.

[78]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[79]  Adrian Ranga,et al.  Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix , 2013, Proceedings of the National Academy of Sciences.

[80]  Mikaël M. Martino,et al.  Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing , 2014, Science.

[81]  Mikaël M. Martino,et al.  Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164 , 2014, Proceedings of the National Academy of Sciences.

[82]  D. Mooney,et al.  Local delivery of VEGF and SDF enhances endothelial progenitor cell recruitment and resultant recovery from ischemia. , 2015, Tissue engineering. Part A.

[83]  W. R. Taylor,et al.  Vasculogenic biosynthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes , 2022 .